Velpatasvir

Velpatasvir
Velpatasvir.svg
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Velpatasvir is an antiviral drug used in combination with other medications for the treatment of hepatitis C virus (HCV) infection. It is a direct-acting antiviral agent that inhibits the NS5A protein, which is essential for viral replication.

Mechanism of Action

Velpatasvir works by targeting the NS5A protein of the hepatitis C virus. NS5A is a non-structural protein that plays a crucial role in the replication of the virus and the assembly of the viral particle. By inhibiting NS5A, velpatasvir disrupts the replication cycle of HCV, thereby reducing the viral load in the body.

Clinical Use

Velpatasvir is commonly used in combination with sofosbuvir, another antiviral medication, to form a fixed-dose combination known as sofosbuvir/velpatasvir. This combination is effective against all six major genotypes of hepatitis C, making it a pan-genotypic treatment option. It is typically administered as a once-daily oral tablet.

Side Effects

Common side effects of velpatasvir, especially when used in combination with sofosbuvir, include headache, fatigue, and nausea. Serious side effects are rare but may include bradycardia when used with amiodarone.

Pharmacokinetics

Velpatasvir is well absorbed when taken orally, with peak plasma concentrations occurring approximately 3 hours after dosing. It is metabolized in the liver and excreted primarily in the feces.

Related pages

• Hepatitis C
• Sofosbuvir
• Direct-acting antiviral

• 
  Velpatasvir